PURE SEC Filing News — PURE Bioscience, Inc.

Latest SEC filings for PURE Bioscience, Inc. (PURE) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-06-15.

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company's technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a ready-to-u…
Sector: Consumer Defensive Industry: Household & Personal Products Market Cap: $9.1M
20
Total Filings
0
Bullish Classifications
0
Bearish Classifications
0
Insider Transactions
12
Material Events (8-K)
8
Periodic Reports
What you're looking at: Each item below is parsed from an actual SEC filing submitted by PURE Bioscience, Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.
PURE Filing Activity Snapshot 2024-10-29 — 2026-06-15
Material Events 12 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 12 in this period for PURE Bioscience, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-06-15

PURE filed 8-K — material company event

PURE BIOSCIENCE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2026-05-05

PURE filed 8-K — material company event

PURE BIOSCIENCE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2026-03-17

PURE filed 8-K — material company event

PURE BIOSCIENCE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2026-02-20

PURE filed 8-K — material company event

PURE BIOSCIENCE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2025-12-15

PURE filed 8-K — material company event

PURE BIOSCIENCE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2025-11-19

PURE filed 8-K — material company event

PURE BIOSCIENCE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2025-10-29

PURE filed 8-K — material company event

PURE BIOSCIENCE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2025-06-16

PURE filed 8-K — material company event

PURE BIOSCIENCE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2025-03-17

PURE filed 8-K — material company event

PURE BIOSCIENCE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2025-01-28

PURE filed 8-K — material company event

PURE BIOSCIENCE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2024-12-16

PURE filed 8-K — material company event

PURE BIOSCIENCE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2024-10-29

PURE filed 8-K — material company event

PURE BIOSCIENCE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Periodic Reports 8 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 2 annual reports (10-K) and 6 quarterly reports (10-Q) for PURE Bioscience, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-06-15

PURE filed Quarterly Report (10-Q)

PURE BIOSCIENCE, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
Form 10-Q Quarterly Report 2026-03-17

PURE filed Quarterly Report (10-Q)

PURE BIOSCIENCE, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
Form 10-Q Quarterly Report 2025-12-15

PURE filed Quarterly Report (10-Q)

PURE BIOSCIENCE, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
Form 10-K Annual Report 2025-10-29

PURE filed Annual Report (10-K)

PURE BIOSCIENCE, INC. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)
Form 10-Q Quarterly Report 2025-06-16

PURE filed Quarterly Report (10-Q)

PURE BIOSCIENCE, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
Form 10-Q Quarterly Report 2025-03-17

PURE filed Quarterly Report (10-Q)

PURE BIOSCIENCE, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
Form 10-Q Quarterly Report 2024-12-16

PURE filed Quarterly Report (10-Q)

PURE BIOSCIENCE, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
Form 10-K Annual Report 2024-10-29

PURE filed Annual Report (10-K)

PURE BIOSCIENCE, INC. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)

How we classify PURE Bioscience, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on PURE. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — PURE SEC Filings

More Tools for PURE

Want deeper PURE analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the PURE stock analysis page.

PURE Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer